Shares of Telomir Pharmaceuticals Inc (NASDAQ:TELO) rose sharply in pre-market trading after the company released promising preclinical study results for its lead compound, Telomir-1.In an SEC Form 8-K filing on Monday, the pre-clinical-stage biotechnology company revealed that its lead compound, Telomir-1, was able to reverse abnormal deoxyribonucleic acid (DNA) methylation in aggressive prostate cancer models.Telomir Pharmaceuticals shares jumped 31% to $1.86 in the pre-market trading session.Here are som ...